Nkarta IPO

7/10/2020

IPO

$252,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: Approximately $65 million to fund our internal discovery research, process development, manufacturing and clinical activities during this time; Approximately $15 million to fund the external costs for the development of NKX101 through the completion of dose finding for NKX101 in hematological malignancies; Approximately $10 million to fund the external costs for the development of NKX019 through the completion of dose finding for NKX019 in B-cell malignancies; Approximately $5 million to fund the external costs for the development of Program 3 to the filing of an IND with the FDA; Approximately $10 million to fund the initial buildout and qualification of our commercial cGMP facility; and the remainder for our other pipeline candidates and general corporate purposes.

Publicly-held

Biopharmaceutical

6000 Shoreline Ct. 102
San Francisco, CA 94080
USA

Undisclosed

Nkarta (Nasdaq: NKTX) seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe.